Novo Nordisk Cuts 5,000 Jobs and Implements Hiring Freeze, Lowers Guidance
Novo Nordisk cut 5,000 Danish jobs during its hiring surge since mid-2022, coinciding with unemployment rising to 3.0% and enforcing a hiring freeze. It has lowered full-year earnings guidance four times, installed a new CEO and warned of negative revenue growth while directing suppliers to expect reduced spending.
1. Danish Workforce Reduction
Novo Nordisk eliminated approximately 5,000 positions in Denmark as part of its strategic review, representing a significant reduction given the company’s rapid hiring surge since mid-2022. This measure coincided with Denmark’s unemployment rate rising to 3.0% and was executed alongside a companywide hiring freeze.
2. Guidance Revisions and Cost Controls
The company has lowered its full-year earnings guidance on four occasions this fiscal cycle to reflect slower top-line growth. A new chief executive has been installed, departmental budgets have been trimmed, and the CFO has notified suppliers to anticipate reduced spending in response to negative revenue projections.
3. Outlook and Market Impact
Novo Nordisk warned of negative growth for the current year, signaling potential challenges ahead. Investors will watch for how cost-control measures and strategic adjustments help stabilize margins and whether the company can reverse the revenue slide in coming quarters.